Lite Strategy held $57.2M in LTC as of June 30

Nasdaq-listed Lite Strategy, formerly MEI Pharma, said it held 832,716 LTC worth $57.22 million as of June 30, the end of its fiscal 2026 year. The company said it had purchased more than 900,000 LTC in total with a $100 million investment after adopting LTC as its primary reserve asset in August last year. Lite Strategy added that its end-June holdings accounted for more than 1% of all LTC mined to date. It also said it has run a covered-call program alongside share repurchases using its LTC holdings, and had bought back 6.4 million shares, equal to about 17% of outstanding shares, as of Sept. 22. Since launching the covered-call program, options premium income totaled about $930,000 through Sept. 22. The company said it plans to focus on increasing LTC holdings per share through further buybacks and additional yield-generation strategies.